RecruitingNot Applicable

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

United States300 participantsStarted 2025-08-21

Plain-language summary

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.
✓. All ages allowed
✓. Suspected or confirmed disease (must meet one of the criteria below):
✓. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)
✓. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery
✓. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:

What they're measuring

Number of participants with ctDNA detected

Timeframe: Approximately 24 months

Trial details

NCT IDNCT06958107

SponsorWake Forest University Health Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-01

Contact for this trial

Meg Lattanze

980-442-4239 Megan.Lattanze@advocatehealth.org

View on ClinicalTrials.gov More Sarcoma trials